MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Omeros Corp

Cerrado

SectorSanidad

3.36 7.69

Resumen

Variación precio

24h

Actual

Mínimo

3.1

Máximo

3.45

Métricas clave

By Trading Economics

Ingresos

-2.1M

-33M

Ventas

412K

412K

Margen de beneficios

-8,121.359

Empleados

202

EBITDA

-1.9M

-35M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+187.54% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-246M

176M

Apertura anterior

-4.33

Cierre anterior

3.36

Noticias sobre sentimiento de mercado

By Acuity

44%

56%

141 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Omeros Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jul 2025, 19:37 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

M3-Brigade Shares Fall on Merger With ReserveOne

8 jul 2025, 23:45 UTC

Charlas de Mercado

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

8 jul 2025, 23:27 UTC

Charlas de Mercado

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8 jul 2025, 23:27 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jul 2025, 23:21 UTC

Charlas de Mercado

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8 jul 2025, 23:21 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 jul 2025, 22:29 UTC

Adquisiciones, fusiones, absorciones

Capricorn to Pay A$1.5 Million in Cash and Shares

8 jul 2025, 22:28 UTC

Adquisiciones, fusiones, absorciones

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8 jul 2025, 21:58 UTC

Charlas de Mercado

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8 jul 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

8 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 jul 2025, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 jul 2025, 19:53 UTC

Charlas de Mercado

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8 jul 2025, 19:53 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 19:45 UTC

Charlas de Mercado

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8 jul 2025, 19:29 UTC

Charlas de Mercado

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8 jul 2025, 19:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Lower -- Market Talk

8 jul 2025, 19:11 UTC

Charlas de Mercado

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8 jul 2025, 19:01 UTC

Charlas de Mercado

Oil Futures Gain With Support From Products -- Market Talk

8 jul 2025, 18:49 UTC

Ganancias

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8 jul 2025, 18:41 UTC

Charlas de Mercado

Mexico's Inflation Seen Mixed in June -- Market Talk

8 jul 2025, 18:38 UTC

Charlas de Mercado

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8 jul 2025, 18:23 UTC

Charlas de Mercado

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8 jul 2025, 18:10 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 18:10 UTC

Charlas de Mercado

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8 jul 2025, 17:24 UTC

Charlas de Mercado

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8 jul 2025, 17:06 UTC

Charlas de Mercado

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Omeros Corp previsión

Precio Objetivo

By TipRanks

187.54% repunte

Estimación a 12 Meses

Media 9 USD  187.54%

Máximo 9 USD

Mínimo 9 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Omeros Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

1

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

6.265 / 7.49Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

141 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.